In order to encourage the R&D of biosimilars, further standardize and guide the design and endpoint selection of biosimilars of pertuzumab injection and provide a technical specification that can be referred to, under the deployment of NMPA, CDE has organized to formulate the Guidance for Clinical Trials of Biosimilars of Pertuzumab Injection, which was issued for implementation on April 21 upon review and approval by NMPA.